Purdue Seeks To Stop Watson's Reformulated Oxy Generic
The complaint alleges that Watson’s abbreviated new drug applications for extended release oxycodone hydrochloride tablets infringe Purdue’s patent for a reformulated version of the drug.
The patent in question, U.S. Patent No. 8,114,383, specifically refers to an “abuse-proofed” form of the drug that is coated in...
To view the full article, register now.